Біосиміляри в терапії цукрового діабету 1 типу: потенційні ризики застосування в пацієнтів дитячого віку
Year: 2017
Type: article
Abstract: In recent years the problem of using biosimilar insulins in patients with diabetes mellitus has become more and more important due to expiration of patents for the most effective insulin preparations, including the «gold standard» of basal insulin therapy of glargine. Presented in this review is the analysis of characteristics of progression of type 1 diabetes in children in the aspect of heightened immune reactivity and active pro-diabetogenic production of antibodies. The analysis of multiple scientific researches proves the necessity of considering high potential risk of using in children and adolescents the insulin preparations with unpredictable properties, presence of which is typical to most of currently existing biosimilars of insulin «Glargine».
Author: Olena Budreiko
Language: Ukrainian
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2898585696